Infectious Complications of Cancer Therapy

Advances in the management of cancer, particularly the development of new chemotherapeutic agents, have greatly improved the survival and outcome of patients with hematologic malignancies and solid tumors; overall 5-year survival rates in cancer patients have improved from 39% in the 1960s to 60% in...

Descripción completa

Detalles Bibliográficos
Autores principales: Safdar, Nasia, Crnich, Christopher J., Maki, Dennis G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2006
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121206/
http://dx.doi.org/10.1007/0-387-31056-8_76
_version_ 1783515150668529664
author Safdar, Nasia
Crnich, Christopher J.
Maki, Dennis G.
author_facet Safdar, Nasia
Crnich, Christopher J.
Maki, Dennis G.
author_sort Safdar, Nasia
collection PubMed
description Advances in the management of cancer, particularly the development of new chemotherapeutic agents, have greatly improved the survival and outcome of patients with hematologic malignancies and solid tumors; overall 5-year survival rates in cancer patients have improved from 39% in the 1960s to 60% in the 1990s.1 However, infection, caused by both the underlying malignancy and cancer chemotherapy, particularly myelosuppressive chemotherapy, remains a persistent challenge.
format Online
Article
Text
id pubmed-7121206
institution National Center for Biotechnology Information
language English
publishDate 2006
record_format MEDLINE/PubMed
spelling pubmed-71212062020-04-06 Infectious Complications of Cancer Therapy Safdar, Nasia Crnich, Christopher J. Maki, Dennis G. Oncology Article Advances in the management of cancer, particularly the development of new chemotherapeutic agents, have greatly improved the survival and outcome of patients with hematologic malignancies and solid tumors; overall 5-year survival rates in cancer patients have improved from 39% in the 1960s to 60% in the 1990s.1 However, infection, caused by both the underlying malignancy and cancer chemotherapy, particularly myelosuppressive chemotherapy, remains a persistent challenge. 2006 /pmc/articles/PMC7121206/ http://dx.doi.org/10.1007/0-387-31056-8_76 Text en © Springer Science+Business Media, Inc. 2006 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Safdar, Nasia
Crnich, Christopher J.
Maki, Dennis G.
Infectious Complications of Cancer Therapy
title Infectious Complications of Cancer Therapy
title_full Infectious Complications of Cancer Therapy
title_fullStr Infectious Complications of Cancer Therapy
title_full_unstemmed Infectious Complications of Cancer Therapy
title_short Infectious Complications of Cancer Therapy
title_sort infectious complications of cancer therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121206/
http://dx.doi.org/10.1007/0-387-31056-8_76
work_keys_str_mv AT safdarnasia infectiouscomplicationsofcancertherapy
AT crnichchristopherj infectiouscomplicationsofcancertherapy
AT makidennisg infectiouscomplicationsofcancertherapy

Ejemplares similares